LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Elenco Azioni・MacroGenics Inc

MacroGenics Inc

Chiusa

SettoreSettore sanitario

4.52 6.1

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.41

Massimo

4.52

Metriche Chiave
By Trading Economics
Entrata	-23M -37M
Vendite	-20M 21M
EPS	-0.58
Margine di Profitto	-177.011
Dipendenti	293
EBITDA	-17M -32M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+39.74% upside

Dividendi
By Dow Jones
Utili prossimi	12 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	89M 276M
Apertura precedente	-1.58
Chiusura precedente	4.52

Notizie sul Sentiment di mercato

By Acuity

50%

151 / 345 Classifica in Healthcare

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 mag 2026, 08:24 UTC

I principali Market Mover

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mag 2026, 21:22 UTC

Utili

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mag 2026, 20:50 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:01 UTC

Discorsi di Mercato

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mag 2026, 14:43 UTC

Discorsi di Mercato

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mag 2026, 14:15 UTC

Discorsi di Mercato

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mag 2026, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

25 mag 2026, 12:58 UTC

Discorsi di Mercato

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mag 2026, 12:56 UTC

Discorsi di Mercato

Utili

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

25 mag 2026, 12:34 UTC

Discorsi di Mercato

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mag 2026, 12:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 mag 2026, 11:00 UTC

Discorsi di Mercato

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mag 2026, 10:19 UTC

Discorsi di Mercato

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mag 2026, 10:05 UTC

Utili

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mag 2026, 10:04 UTC

Utili

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mag 2026, 10:03 UTC

Utili

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mag 2026, 10:02 UTC

Utili

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mag 2026, 10:01 UTC

Utili

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mag 2026, 10:00 UTC

Utili

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q EPS MYR0.1883

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Rev MYR17.1B

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Net MYR1.1B

25 mag 2026, 09:38 UTC

Discorsi di Mercato

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mag 2026, 08:55 UTC

Discorsi di Mercato

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

39.74% in crescita

Previsioni per 12 mesi

Media 6.33 USD 39.74%

Alto 9 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a MacroGenics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

151 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.